Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
The road to (2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-Uridine stretches back to the early efforts of chemists working on nucleoside modifications amid lofty dreams of new therapeutics. Lab benches in the 1970s and 1980s saw vigorous efforts to tweak sugar moieties and bases, spinning nature’s blueprints into improved drugs. In that quest, fluorine showed up as a game-changer. Its introduction onto ribose rings shifted the stability and biological uptake of nucleoside analogs. Later, with the addition of a methyl group on the 2' position, researchers could dodge enzymatic degradation and tune selectivity for viral polymerases over host enzymes. This compound’s development wasn’t a straight shot. Each small advance demanded years of work and plenty of failures. What stands out is the tight interplay between academic discovery and pharmaceutical industry muscle, all drawn by the hope to treat tough diseases like viral infections and certain cancers.
This modified uridine earns attention in pharmaceutical pipelines, especially where RNA stability and base-pairing fidelity matter. Its molecular structure, defined by a fluoro group and a methyl slap on the 2' carbon of deoxyribose, grants special resistance to metabolic breakdown. The BP, EP, and USP grades show it has cleared major regulatory hurdles, with each label standing for British, European, and United States pharmacopeial standards. This is not a laboratory novelty; this nucleoside sees real consideration for clinical use, filling demand for quality, purity, and traceability.
On the shelf, (2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-Uridine shows up as a white to off-white crystalline solid. Its molecular weight clocks in at 262.22 g/mol, with a melting range around 162–166°C. I’ve watched it dissolve cleanly in water and DMSO—two workhorse solvents for both benchwork and production lines. Its stability in room air, away from direct heat and light, offers comfort for anyone worried about stockroom spoilage. The fluoro and methyl modifications yield sharper resistance to acid and enzymatic conditions, which directly affects how pharmaceutical scientists design next-generation oligonucleotides and prodrugs.
On any label that meets pharmacopeial requirements, purity jumps out first—no less than 99%. Heavy metals should not creep above 10 ppm. Residual solvents, if any, stay below 0.05%. Identification checks require a strict match for both retention time in HPLC and spectral features in NMR and mass spec. Every vial should promise a reliable lot number, manufacturing date, and expiration, backed by COA documentation. Handling guidance draws from safety data, and all information appears clear in language any researcher can follow, not buried in legalese. Certifications must line up with line audits and the traced source of raw materials.
Preparation begins with an uridine scaffold. The journey from simple uridine to this modified analog demands careful orchestration of steps. Protection of select hydroxyls on deoxyribose comes first, paving the way for targeted substitution. Electrophilic fluorination, usually with reagents like DAST or Deoxo-Fluor, drops the –F group onto the 2' carbon. Next, a methyl source slots in next to the fluorine, with reductive methylation often playing the hero. After each step, purification by column and crystallization ensures no scrubby byproducts remain. Deprotection and more rounds of chromatography give a product fit for pharmaceutical development—and for those at the bench, meticulous cleaning between steps cuts risks of cross-contamination to keep the final purity on target.
The utility of this compound shines brightest in reactions that generate custom oligonucleotides. The 2'-fluoro methyl pattern isn’t easy to install on a growing chain, but the modification locks in conformational preferences and resists messy side reactions often triggered by other chemical handles. Once included in a sequence, the analog benefits synthetic chemists by allowing further derivatization—think conjugation to delivery vectors, or phosphorylation for prodrug design. I’ve seen this analog used to cap oligos against exonuclease digestion, a useful trick in cell culture and animal studies. Its influence extends into structure-guided design for siRNA, aptamers, and antisense technologies, where improved thermal stability can change both in vitro and in vivo performance.
Not every supplier sticks to the same naming. You may see this nucleoside sold as 2'-deoxy-2'-fluoro-2'-methyluridine, or under supplier abbreviations like FMeUrd. Catalogs and MSDS sheets sometimes prefer systematic names from IUPAC, which can stretch to nearly a dozen words. The variety in naming urges attention while sourcing; an incorrect synonym can derail an entire drug synthesis or lead to accidental mixing with similar but functionally distinct analogs.
Even with all the promise this analog brings, no one in the lab ignores rigorous safety. Dust inhalation raises respiratory concerns; careful weighing and solution handling in fume hoods become non-negotiable. Eye and skin exposure, though unlikely, receives coverage through gloves and goggles—just as regulators and best practices demand. Spillage calls for a wipe-down with suitable solvents, never a casual sweep, to avoid hidden exposure risks. Waste handling involves collecting organic residues as hazardous waste, always labeled and logged, which matches both chemical hygiene rules and site audits. For the pharma grade, operational records track every step from synthesis to shipment, a demand from both regulatory agencies and downstream clients counting on the highest integrity standards.
Its core application sits firmly in medical research and drug development. Modified oligonucleotide therapies pull this compound into antisense, RNAi, and mRNA stabilization projects. Some labs use it in probes and primers where longer shelf life and reduced background carry real value. Behind most biomedical uses lies the simple fact that this nucleoside blocks quick destruction by intracellular nucleases; you get more signal, more activity, and fewer headaches with batch-to-batch consistency. Pharmaceutical manufacturing picks it for integration into candidate therapies for cancer, viral infection, and rare genetic conditions. The big deal comes from clinical studies that ask for higher safety margins; this nucleoside meets analytical expectations head-on.
Over the past decade, research groups—from university departments to sprawling pharmaceutical outfits—have pushed this analog into new areas. Investigators aren’t just plugging it into model systems; they’re drafting large-scale protocols to support preclinical and IND-stage trials. RNA therapeutics ride high on the wave of modified nucleosides, and this fluoromethyl variant fares well in animal models, showing promising pharmacokinetics and bioavailability. Industry has stepped up with process development to scale up synthesis, troubleshooting crystalline purity, and regulatory documentation for future commercial batches. Cross-lab collaborations feed back data about bioactivity and off-target profiles, building confidence that this analog delivers meaningful results.
Every new analog starts in petri dishes and test tubes, then walks the long road through rodent models and sometimes higher animals. Toxicity profiles show low acute toxicity when handled wisely, but accumulation and long-term effects remain tightly monitored. Studies highlight a major plus: reduced cytotoxicity compared to some harsh analogs, with side effects that rarely breach the limits of concern at clinical trial doses. Still, no one gets complacent. Metabolic fate in liver and kidney matters most, and teams watch for any hint of delayed organ impact or metabolites with unexpected biological activity. Data reporting follows GLP standards, and safety signals prompt adjustment long before human dosing.
Looking ahead, the horizon opens wide for this nucleoside and its cousins. Experience tells me that the demand for robust, stable, and bioactive RNA and DNA analogs won’t slow down—especially with the explosion of interest in genetic medicines. Chemists have started mapping hybrid modifications, painting in new chemical groups to overlap efficacy against pathogens and tumors. Drug companies are sizing up commercial-scale production for next-generation drugs, and the challenges feel more like puzzles than brick walls. If regulators stick to transparent science, and if makers stick to quality, this analog holds its spot among the building blocks of RNA therapeutics, with a future built on clinical data, integrity, and inventiveness shaped by years of learning and hard-won experience.
(2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-Uridine isn’t a name rolling off the tongue, but in the world of medicine, it’s pivotal. Scientists turn to this compound when seeking an edge against tough viruses and genetic diseases. Most folks never hear about it, but if you’ve heard of mRNA vaccines or RNA-based treatments, you’ve crossed paths with its handiwork. This modified nucleoside shows up in labs hungry for safer, more stable genetic therapies.
The buzz around RNA medicines grows louder every year. RNA strands break down fast, and our immune system doesn’t always cooperate. Here’s where chemical tweaks matter. Adding a fluorine and a methyl group to uridine creates (2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-Uridine. This small shift blocks enzymes that chop up the RNA, and it tames immune cells that otherwise punch back at new treatments. So mRNA vaccines and therapies stick around longer and work harder with less fuss from the body.
Resistance to old-school antivirals pops up fast, especially with mutating viruses like hepatitis C and HIV. Researchers found that using modified nucleosides like this one gives an upper hand. It fools viruses into thinking they’re working with their normal building blocks. They trip up when replicating, stalling out viral spread. Trials show these drugs can block the chain reaction viruses need to survive. It’s not just a theory—antiviral drugs built on this backbone have moved from lab benches to patients’ hands.
Rare, crippling diseases often trace back to broken genes or faulty genetic messages. Getting new, healthy RNA into cells could rewrite the story for patients facing limited options. (2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-Uridine boosts stability, lowering the risk that delivered RNA gets shredded before it can help. This is especially true for therapies aiming to “silence” bad genes, like certain forms of muscular dystrophy or genetic liver diseases. Companies like Alnylam and Moderna have leaned on nucleoside modification to push several drugs through clinical trials and into the real world.
Optimism runs high, yet risks remain. Chemical tweaks in RNA could bring unknown long-term side effects or prompt new immune responses no one predicted. Careful tracking in big clinical studies keeps everybody honest, particularly once treatments exit the research stage and reach a wider range of people. Regulators look for consistent manufacturing and long-term safety data. Open conversations between scientists, doctors, and patients can flag problems before trust takes a hit.
The pharmaceutical scene keeps racing ahead. Solutions rarely stay static. In my time around doctors, patients, and research labs, everyone seeks faster paths to cures. The biggest leaps came when companies shared data and regulators stayed flexible without cutting corners. More funding for basic science, and opportunities for smaller groups to join research, keep these options growing. Strategic investment, regular safety watchdogs, and steady information for the public all gear the field toward less trial-and-error and more real solutions.
The takeaway: (2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-Uridine stands as a building block for groundbreaking new therapies, letting RNA treatments last longer and work better. Getting it right requires careful balance—pushing innovation, but never forgetting the lessons learned from taking things too fast in medicine. The hope is strong. The need for steady, open science stands even stronger.Quality in pharmaceutical manufacturing has always felt like walking a tightrope. Producers strive for nothing but the best because lives really do hang in the balance. (2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-Uridine stands out as a nucleoside analog often tapped in antiviral research and emerging therapies. Its purity, consistency, and identification under the British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP) rules each demand proof and discipline. It’s never about just hitting a number—it’s about showing reliability batch after batch.
Remembering my time helping a lab manage a clinical trial, I saw several batches panic-checked after traces of phosphate threatened to spoil a whole lot. If you ask any chemist on the bench, they’ll tell you: a single impurity rolling in above allowed limits can stop distribution cold. For (2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-Uridine, most buyers expect a minimum assay (purity) of at least 98.0% (often, companies push above 99.0% for added safety). All three pharmacopeias aim for clean stuff, but they each specify slight differences in what “clean” means by their books.
Let’s break it down: Identity checks call for techniques like HPLC, NMR, or mass spectrometry, not just to confirm it’s the right compound, but that no leftover synthesis chemicals are hiding in the mix. Appearance—a white to off-white powder—also matters because color or texture shifts often flag trouble before machines do. Residual solvents usually cannot exceed tight limits (ethanol less than 5000 ppm, for one), with solvent choices sometimes limited by region. Heavy metals, arsenic, and related stuff land squarely under 10 ppm, not only to meet rules but to keep patient safety in focus. Water matters, too; excess moisture eats away at stability, so Karl Fischer titration or similar methods peg loss on drying below 1.0–2.0%.
Production lines rarely get away with ignoring impurities below 0.1%. Sometimes, you find related substances—other nucleosides or unreacted starting materials—sneaking in at the end. BP and EP both lay out individual and total impurity limits, with USP threading close behind. Spotting a rogue fluorinated impurity above 0.10%? Throw that batch out or bring it back through purification; you can’t fudge these numbers, especially if an inspector drops by.
Quality control teams catch a lot of flak for delays, but those hard stops come from real risks. Miss a contaminant, and somebody gets sick—or a whole program tanks. In one tough season, our team shredded nearly a month of work due to off-spec UV readings. Sure, it stung, but the trust we built with investigators paid off as the project moved forward clear-eyed.
Better solvent recovery, closed-system synthesis steps, and extra chromatographic runs stand out as direct fixes. Still, I’ve learned sharp attention to training makes just as big a difference. Catching contamination early, before it drifts into scale-up batches, saves companies from cost overruns and recalls. EP and USP encourage limits on bioburden too, so cross-checking for microbial growth between steps isn’t wasted time.
Ultimately, (2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-Uridine highlights a tough but honest lesson: the value of sticking to clear, unforgiving standards. The sense of relief from shipping out a certified batch or the dread of a recall letter—those feelings don’t just come from numbers, but from the real impacts on patients and researchers everywhere.
For anyone handling products, clear recommendations on storage conditions can make or break a reputation. Heat, moisture, and sunlight act fast. Years ago, I learned this the hard way at a community food bank. Boxes of dry goods stacked close to a warm window started to fade and sweat on hot days, leaving us with donations that barely stayed edible. There’s no shortcut to honest handling—cutting corners just comes back to haunt you.
Storing products in a cool, dry space with low humidity helps slow down degradation. Temperature swings cause condensation and let moisture slip in; from experience, this is when a product's quality nosedives. Particularly with perishable or delicate items, high heat can spark unwanted chemical changes that can make them either unsafe or just unusable. The U.S. Food and Drug Administration (FDA) flags 20 to 25°C (68–77°F) as the safest bet for many items, yet it’s up to everyone in the supply chain to check their own environment and keep it in check. It’s easy to ignore details—until you lose money or someone winds up with a product that simply doesn’t work.
Shelf life isn’t a guess. Scientific testing tells us how long an item keeps its integrity, whether it's medication, packaged snacks, or lab reagents. Each product handles time differently. For food, shelf life can depend on oil content or exposure to air; for chemicals, purity can scrape away quicker with just a minor mishap in sealing jars or bottles. Labels must spell out expiration or best-by dates plainly, and I always remind people to look at those numbers before they open their wallets or stash items in a back closet. Skipping this step means risking waste—or worse, harming someone who trusts your word.
Guidelines from regulatory agencies back up shelf life claims with real data. For instance, the World Health Organization pushes for ongoing stability tests that mimic shipping conditions, not just ideal lab storage. Following their lead isn’t just red tape—it’s how businesses earn trust and keep their customers healthy. When companies cut the truth or try to fudge dates, they burn bridges fast. I’ve seen loyal customers turn away from brands after just one bad headline about spoiled goods or recalls.
Proper storage starts at the factory and runs through the warehouse to individual homes. Everyone in that chain faces the risk of a storage mistake. That’s why regular checks on temperature and humidity, honest reporting, and solid packaging make all the difference. Take small steps. Add monitors to your storage areas. Rotate stock so the oldest gets used first. Double-check that seal before shelving a shipment.
When something starts to slip—smells off, looks odd, or the texture changes—don’t ignore it. Pull questionable products before they reach customers. Talking openly about storage and shelf life doesn’t make your product look weak; it signals care and respect for everyone counting on you. This kind of transparency builds a foundation for strong partnerships up and down the supply chain. Responsible storage isn’t about ticking boxes. It’s about keeping promises.
Certificates of Analysis (COA) and Material Safety Data Sheets (MSDS) aren’t just paperwork filling up binders or USB drives. They are lifelines for anyone working with chemicals, drugs, ingredients, or new materials. Years ago, at a manufacturing plant, I saw firsthand what happens without solid documentation—two tons of product went straight to waste because no one could verify its composition. Quality and safety hang in the balance when you don't have reliable records.
Regulatory documents serve real people, not just a legal department. If a supplier can show a COA, everyone down the line—from the purchasing team to the technician in the lab—knows what’s actually in those barrels or powders. A COA lets you check purity, look for heavy metals, see if bacteria are lurking, and confirm specifics like melting points. It’s proof, clear and simple, that you’re getting what’s promised.
An MSDS does even more. It spells out the health risks, fire hazards, required personal protection, cleanup advice, and storage directions. I remember seeing an MSDS for a common lab solvent and finding warnings about toxic fumes. No one assumed the product would be benign; the sheet kept everyone sharp. Having these docs stops guesswork and protects both workers and neighbors.
Regulators don’t just “recommend” COA and MSDS—they demand them. Both FDA and OSHA expect full records, and so do their counterparts in Europe, Asia, and beyond. Imagine a customs official asking for these papers and the shipment coming up empty; delays, fines, and destroyed goods can follow. Missing records can grind a project to a halt, kill a launch, or spark lawsuits after an injury.
If someone drags their feet when asked for documentation, think twice. I once worked with a supplier whose COA had missing fields and no signature. We cut ties, and later, their batch failed a random test. Valid documentation separates professionals from amateurs.
Some companies keep older COAs, thinking last year’s numbers still work. Ingredients change. Processes evolve. Each batch should match its own test results. Otherwise, there's no real traceability, and surprises pop up where they hurt most—in final products.
Reliable suppliers keep digital libraries, accessible with a login. At another plant, a QR code on each drum brought up the latest COA and MSDS—smart, quick, and no paperwork to lose. Once you receive a shipment, reading through the MSDS and confirming test results pays off every time. People who work with chemicals or new materials can’t just hope for the best. They hold the company’s reputation—and their own safety—in their hands.
Strong documentation builds trust across teams. In regulated industries, everyone needs solid facts on hand. Keeping that chain unbroken keeps risks and disasters at bay, and lets people focus on creating good products, not fixing preventable messes.
In pharma supply chains, clarity around packaging translates to less confusion and faster uptake in clinical research and manufacturing settings. Most labs and companies ask suppliers for clear figures. Based on current industry practice, 2'R-2'-Deoxy-2'-Fluoro-2'-Methyl-Uridine, a key nucleoside for oligonucleotide synthesis and antiviral R&D, typically gets shipped out in glass vials or HDPE bottles. These containers usually hold amounts ranging from one gram up to ten or fifty grams per bottle—smaller packages suit research screening, larger ones support pilot or production scales. Some suppliers bundle larger custom lots for established clients, making sure to run quality checks across batches.
From experience helping set up molecular biology labs, I know that packaging has to fit the workflow. There’s no patience in this field for leaky seals or static build-up that threatens ultra-pure nucleoside stock. Pharma-grade means everything comes in inert packaging, with desiccants tucked in and paperwork tracking every step from synthesis. Crack open a ten-gram bottle and there’s a real sense of confidence because the dry weight matches the COA, and you know nobody’s cut corners.
Speed often becomes the sticking point. For in-stock material sitting at a U.S. or European distribution center, shipment leaves the premises within two to five business days. Regular express couriers like FedEx and DHL knock the door after one to four days, depending on customs and address. For companies located in Asian manufacturing hubs, air freight delivers with similar timelines, but customs at the receiving end throws in a wild card. I’ve seen shipments stuck a week because a customs broker wanted another document—never pleasant but not rare for pharmaceutical-grade reagents.
Out-of-stock or custom orders have a longer lead time. Most nucleoside suppliers quote a four to eight week manufacture window before your gram arrives. The molecule is specialty chemistry, so synthesis, purification, and quality control each eat up calendar time. Some large multinational suppliers sometimes hold buffer stocks and slice delivery to under two weeks, especially if previous clients signal big upcoming orders.
Missed deadlines cascade through drug discovery projects. If a team waits an extra ten days for new nucleoside, cell assays and RNA oligo synthesis work grind to a halt—lab techs cannot run negative controls, and project managers get stuck juggling timelines. Being able to call a supplier and get a clear, honest delivery estimate makes budgets go further and teams happier. Quality assurance comes up every time, too. Nobody bets a full RNA batch on a shipment without seeing an HPLC trace and impurity profile.
Supply chain hiccups aren't just frustrating. They pull up the price of R&D and put lives waiting for new therapies on hold. Over the years, I’ve watched the most experienced researchers go straight to suppliers who communicate clearly, deliver documents with the goods, and respond fast when shipments go sideways. Keeping stock of critical nucleoside analogs isn’t glamorous, yet every year organizations pay more for expedited shipping than a robust inventory system would cost.
Gaps in supply and unclear timelines call for stronger partnerships. More inventory near big biotech clusters could shave days off lead times. Digital tracking that lets labs monitor a shipment from China to a San Francisco benchtop cuts back on anxiety. Straightforward communication about backorders and real-time updates reduce the risk of costly surprises.
Clear and steady supply chains for 2'R-2'-Deoxy-2'-Fluoro-2'-Methyl-Uridine save time, money, and morale in a field where big discoveries ride on reliable daily deliveries.
| Identifiers | |
| CAS Number | 163521-08-2 |
Chengguan District, Lanzhou, Gansu, China
